| 07/01/22 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 06/01/22 | Notification about results of final buy-back of shares | AQ |
| 30/12/21 | Notification about final share buy-back | AQ |
| 28/12/21 | Correction: Regarding results of a share buy-back offer | AQ |
| 28/12/21 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 31/12/2025 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 31/12/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 18/06/2021 | |
Janis Buks
CHM | Chairman | - | 31/08/2022 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04/08/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| -0.08% | -1.43% | +15.99% | +67.26% | 47.74B | |
| -3.21% | +1.37% | +52.36% | +125.75% | 41.7B | |
| -0.40% | -1.23% | -10.08% | +16.08% | 12.14B | |
| +1.11% | -1.34% | +13.61% | +71.49% | 11.55B | |
| 0.00% | 0.00% | +30.00% | +147.62% | 9.18B | |
| -0.39% | +0.62% | +19.93% | +39.54% | 7.54B | |
| -1.35% | +0.74% | +47.03% | -11.93% | 7.35B | |
| -0.64% | -0.02% | +19.42% | +199.06% | 6.88B | |
| +2.65% | -3.55% | -31.27% | +24.03% | 5.72B | |
| Average | +0.49% | -0.63% | +17.44% | +75.43% | 16.64B | |
| Weighted average by Cap. | -0.87% | -0.54% | +24.75% | +83.77% |
Employees
2,191
Sector
Pharmaceuticals
